Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy

European Journal of Endocrinology

Volumn 144, Issue 5, 2001, Pages 467-473

  Siggelkow, Heide ^a   Melzer, Ariane ^a   Nolte, Wilhelm ^a   Karsten, Klara ^a   Höppner, Wolfgang ^b   Hüfner, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Inst for Horm and Fertil R   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; CYTOSINE; GUANINE; LEVOTHYROXINE; ONCOPROTEIN; PENTAGASTRIN; PHENYLALANINE; PROTEIN RET; THYMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CAUSE OF DEATH; CERVICAL LYMPH NODE; CHILD; CHILDHOOD CANCER; CODON; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; EVOLUTION; EXON; EXPERIENCE; FAMILIAL CANCER; FAMILY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; GERM LINE; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PATIENT MONITORING; PHENOTYPE; PHEOCHROMOCYTOMA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTO ONCOGENE; SCREENING; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR GROWTH;

EID: 0034997254     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1440467     Document Type: Article

References (31)

1. Schimke RN. Genetic aspects of multiple endocrine neoplasia. Annual Review of Medicine 1984 35 25-31.
2. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993 363 458-460.
3. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association 1996 276 1575-1579.
4. McMahon R, Mulligan LM, Healey CS, Payne SJ, Ponder M, Ferguson SM et al. Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Human Molecular Genetics 1994 3 643-646.
5. Marsh DJ, Robinson BG, Andrew S, Richardson AL, Pojer R, Schnitzler M et al. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994 23 477-479.
6. Feldman GL, Kambouris M, Talpos GB, Mulligan LM, Ponder BA & Jackson CE. Clinical value of direct DNA analysis of the RET proto-oncogene in families with multiple endocrine neoplasia type 2A. Surgery 1994 116 1042-1047.
7. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A [see comments]. New England Journal of Medicine 1994 331 828-835.
8. Wells SJ, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Annals of Surgery 1994 220 237-247.
9. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham GH, Jansen-Schillhorn van Veen JM et al. From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. Journal of Internal Medicine 1995 238 347-356.
10. Dralle H, Gimm O, Simon D, Frank RK, Gortz G, Niederle B et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World Journal of Surgery 1998 22 744-750.
11. Gill JR, Reyes MM, Iyengar S, Kidd KK, Touloukian RJ, Smith C et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. Journal of Pediatrics 1996 129 459-464.
12. Wells SJ & Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Experimental and Clinical Endocrinology and Diabetes 1998 106 29-34.
13. Norton JA, Froome LC, Farrell RE & Wells SJ. Multiple endocrine neoplasia type IIb: the most aggressive form of medullary thyroid carcinoma. Surgical Clinics of North America 1979 59 109-118.
14. Wells SJ & Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Experimental and Clinical Endocrinology and Diabetes 1998 106 29-34.
15. Ponder BA. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Research 1999 S1736-S1741: discussion S1742.
16. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 1999 18 3919-3922.
17. Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. Journal of Clinical Endocrinology and Metabolism 1996 81 1780-1783.
18. Kambouris M, Jackson CE & Feldman GL. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Human Mutation 1996 8 64-70.
19. Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ & Ploos van Amstel HK. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Human Genetics 1996 97 11-14.
20. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 1993 2 851-856.
21. Oriola J, Paramo C, Halperin I, Garcia MR & Rivera FF. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma. American Journal of Medical Genetics 1998 78 271-273.
22. Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G et al. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology 1998 139 3613-3619.
23. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Fransiscis V et al. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Research 1997 57 391-395.
24. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T et al. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 1998 17 2851-2861.
25. Moers AM, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IA, Blijham GH et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. American Journal of Medicine 1996 101 635-641.
26. Egawa S, Futami H, Takasaki K, Iihara M, Okamoto T, Kanbe M et al. Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan [see comments]. Japanese Journal of Clinical Oncology 1998 28 590-596.
27. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995 10 2415-2419.
28. Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E et al. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Human Mutation 1998 S167-S171.
29. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG→ATG) mutation. Surgery 2000 128 93-98.
30. Niccoli-Sire P, Murat A, Baudin E, Henry J-F, Proye C, Bigorgne J-C et al. Early of prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. European Journal of Endocrinology 1999 141 468-474.
31. Melzer A, Siggelkow H, Höppner W & Hüfner M. Presentation of a large kindred with familial medullary thyroid carcinoma demonstrating low grade malignancy. Experimental and Clinical Endocrinology and Diabetes 1999 107 S70.